文献速递临床试验与 GCP

痛风缓解期患者降尿酸治疗采用达标持续策略与避免症状停药策略的比较(GO TEST Finale):多中心实用性随机优效性试验的研究方案

Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial.
PubMed 文献 · Trials · 2023-04-19

本研究为研究者发起的实用性、开放标签、多中心、随机优效性治疗策略试验,计划纳入至少278例使用降尿酸治疗且缓解>12个月的痛风患者,1:1随机分为持续达标治疗(目标血清尿酸<0.36 mmol/l)或转换为避免症状的停药策略(逐渐减停,出现持续或复发发作时重启)。主要结局为24个月随访最后6个月未缓解患者比例的组间差异,采用两比例z检验分析。

要点

  • 持续达标策略目标血清尿酸<0.36 mmol/l,避免症状策略逐渐减停并在持续或复发发作时重启。
  • 主要结局为24个月随访最后6个月未缓解患者比例的组间差异。
  • 次要结局包括痛风发作发生率、降尿酸治疗重启或调整、抗炎药物使用、血清尿酸变化、不良事件及成本效果。

核心结论

  • 该研究将是首个在痛风缓解期患者中比较两种降尿酸治疗策略的临床试验,有助于制定更具体明确的指南推荐并改善长期痛风治疗的成本效果,也为个体化长期降尿酸治疗探索道路。

研究设计与样本

  • 研究者发起的实用性、开放标签、多中心、随机、优效性治疗策略试验(GO TEST Finale)。
  • 计划纳入至少278例使用降尿酸治疗且处于缓解(>12个月,初步痛风缓解标准)的痛风患者,1:1随机分组。

主要发现

  • 主要结局为24个月随访最后6个月未缓解患者比例的组间差异,采用两比例z检验分析。
  • 次要结局包括痛风发作发生率、降尿酸治疗重启或调整、抗炎药物使用、血清尿酸变化、不良事件(特别关注心血管和肾脏事件)及成本效果。

关键数值与推荐

  • 持续达标治疗策略的目标为血清尿酸<0.36 mmol/l。
  • 缓解定义为>12个月(初步痛风缓解标准)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term gout treatment is based on reducing serum urate levels using urate-lowering therapy (ULT). Most guidelines recommend using a lifelong continuation treat-to-target (T2T) strategy, in which ULT is dosed or combined until a serum urate target has been reached and maintained. However, a frequently used alternative strategy in clinical practice is a treat-to-avoid-symptoms (T2S) ULT discontinuation strategy, with the possibility of restarting the medication. This latter strategy aims at an acceptable symptom state, regardless of serum urate levels. High-quality evidence to support either strategy for patients in prolonged remission while using ULT is lacking. METHODS: We developed an investigator-driven pragmatic, open-label, multicentre, randomized, superiority treatment strategy trial (GO TEST Finale). At least 278 gout patients using ULT who are in remission (>12 months, preliminary gout remission criteria) will be randomized 1:1 to a continued T2T strategy (treatment target serum urate < 0.36 mmol/l) or switched to a T2S discontinuation strategy in which ULT is tapered to stop and restarted in case of (persistent or recurrent) flaring. The primary outcome is the between-group difference in the proportion of patients not in remission during the last 6 months of 24 months follow-up and will be analyzed using a two proportion z test. Secondary outcomes are group differences in gout flare incidence, reintroduction or adaptation of ULT, use of anti-inflammatory drugs, serum urate changes, occurrence of adverse events (with a special interest in cardiovascular and renal events), and cost-effectiveness. DISCUSSION: This study will be the first clinical trial comparing two ULT treatment strategies in patients with gout in remission. It will contribute to more specific and unambiguous guideline recommendations and improved cost-effectiveness of long-term gout treatment. It also paves the way (exploratory) to individualized long-term ULT treatment. In this article, we elaborate on some of our trial design choices and their clinical and methodological consequences. TRIAL REGISTRATION: International Clinical Trial Registry Platform (ICTRP) NL9245. Registered on 2 February 2021 (METC Oost-Nederland NL74350.091.20); EudraCT EUCTR2020-005730-15-NL. Registered on 11 January 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Peeters IR, den Broeder AA, Taylor WJ, et al. Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial. Trials. 2023. PMID: 37072799. doi:10.1186/s13063-023-07242-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。